XML 47 R28.htm IDEA: XBRL DOCUMENT v2.3.0.15
Share-Based Compensation (Tables)
12 Months Ended
Sep. 30, 2011
Share-Based Compensation [Abstract] 
Compensation cost relating to share based payments
 
                         
    2011     2010     2009  
 
Cost of products sold
  $ 14,440     $ 15,128     $ 16,846  
Selling and administrative expense
    49,536       54,423       58,920  
Research and development expense
    9,387       9,823       10,808  
                         
    $ 73,363     $ 79,374     $ 86,574  
                         
Assumptions for estimation of the fair values of stock appreciation rights granted during the reporting periods
 
             
    2011   2010   2009
 
Risk-free interest rate
  2.40%   2.60%   2.73%
Expected volatility
  24.00%   28.0%   28.0%
Expected dividend yield
  2.14%   1.96%   2.11%
Expected life
  7.8 years   6.5 years   6.5 years
Fair value derived
  $16.80   $19.70   $16.11
Summary of SARs outstanding
 
                                 
                Weighted
       
                Average
       
          Weighted
    Remaining
    Aggregate
 
          Average
    Contractual Term
    Intrinsic
 
    SARs     Exercise Price     (Years)     Value  
 
Balance at October 1
    7,659,155     $ 70.46                  
Granted
    2,216,436       76.64                  
Exercised
    (555,155 )     66.58                  
Forfeited, canceled or expired
    (293,399 )     72.71                  
                                 
Balance at September 30
    9,027,037     $ 72.14       7.07     $ 35,203  
                                 
Vested and expected to vest at September 30
    8,584,694     $ 72.03       7.00     $ 34,346  
                                 
Exercisable at September 30
    4,603,602     $ 70.09       5.85     $ 26,631  
                                 
Summary of stock options outstanding
 
                                 
                Weighted Average
       
          Weighted
    Remaining
    Aggregate
 
    Stock
    Average
    Contractual Term
    Intrinsic
 
    Options     Exercise Price     (Years)     Value  
 
Balance at October 1
    6,433,148     $ 38.12                  
Granted
                           
Exercised
    (2,927,278 )     35.28                  
Forfeited, canceled or expired
    (48,519 )     32.22                  
                                 
Balance at September 30
    3,457,351     $ 40.61       2.04     $ 113,078  
                                 
Vested and expected to vest at September 30
    3,457,351     $ 40.61       2.04     $ 113,078  
                                 
Exercisable at September 30
    3,457,351     $ 40.61       2.04     $ 113,078  
                                 
Summary of performance-based restricted stock units outstanding
 
                 
          Weighted
 
    Stock
    Average Grant
 
    Units     Date Fair Value  
 
Balance at October 1
    2,879,568     $ 72.79  
Granted
    944,174       76.64  
Distributed
    (122,554 )     84.29  
Forfeited or canceled
    (798,254 )     82.24  
                 
Balance at September 30(A)
    2,902,934     $ 70.96  
                 
Expected to vest at September 30(B)
    234,015     $ 70.32  
                 
 
 
(A) Based on 200% of target payout.
 
(B) Net of expected forfeited units and units in excess of the expected performance payout of 180,182 and 2,488,737, respectively.
Summary of time-vested restricted stock units outstanding
 
                 
          Weighted
 
    Stock
    Average Grant
 
    Units     Date Fair Value  
 
Balance at October 1
    1,808,295     $ 70.90  
Granted
    600,651       76.97  
Distributed
    (301,196 )     80.46  
Forfeited or canceled
    (197,080 )     77.77  
                 
Balance at September 30
    1,910,670     $ 70.59  
                 
Expected to vest at September 30
    1,719,603     $ 70.59